Skip to main content
. Author manuscript; available in PMC: 2022 Dec 15.
Published in final edited form as: Cancer Res. 2022 Jun 15;82(12):2313–2326. doi: 10.1158/0008-5472.CAN-21-4145

Figure 4. NR2F1 inhibits systemic dissemination of MMTV-HER2 ECCs.

Figure 4.

A. Tumor volume measurements in nude mice orthotopically injected with shControl and shNr2f1 MMTV-HER2 ECCs or MMTV-HER2 tumor-derived (PT) cells. B. Percentage of PH3+ cells/acinus in mammary glands orthotopically injected with shControl or shNr2f1 MMTV-HER2 ECCs 10-16 day post-injections. N=2 mice/group. C. Experimental design for detection of eDCCs in nude mice 10-16 days after ortothopic injection with shControl and shNr2f1 MMTV-HER2 ECCs. N=4mice/group. D. Number of eDCCs (HER2+) per lung area as described in C. Number of DCCs= 4,399 shControl; 4,305 shNr2f1. Representative image shown, scale bar=5 μm. E. Percentage of PH3+/HER2+ lung eDCCs as described in C. Number of eDCCs= 4,399 shControl; 4,305 shNr2f1. Image depicts a PH3+ eDCCs, scale bar=5 μm. For all graphs, mean (dotplot) or mean±SD (bar graphs) is shown and student’s unpaired t- test, unless otherwise noted.